View Older Stories View More Recent Stories
-
UBS Reiterates Buy Rating on CIGNA (CI)
-
Cantor Fitzgerald says CMS' new audit strategy has logistical challenges
-
Cigna Corp. (CI) call put ratio 1 call to 1.2 puts
-
Cigna Corp. (CI) call put ratio 1.1 calls to 1 put as share price down 1.5%
-
Bernstein: 'We See the Reaction to PBM Stocks as Off Target'
-
Cigna Corp. (CI) May 205 puts, June 350 puts and May 330 calls active as share price down 5.6%
-
CVS Health (CVS), Others Fall After Trump Said Will Cut out Middle Man on Drugs
-
CIGNA (CI) PT Raised to $373 at Bernstein, Reflecting 'Modestly Lower Policy Risk'
-
CFRA: Cigna Group ’faces industry-wide cost pressures’
-
CFRA Downgrades CIGNA (CI) to Hold
-
CIGNA (CI) PT Raised to $385 at Raymond James
-
CIGNA (CI) PT Raised to $397 at Jefferies
-
Cigna Corp. (CI) Tops Q1 EPS by 39c
-
Cigna Corp. (CI) call put ratio 1 call to 3.7 puts with a focus on May 2 weekly puts into quarter results
-
Guggenheim Starts CIGNA (CI) at Buy
-
Trump Administration Medicare Insurer Rate Increase Doubles Prior Proposal -- WSJ
-
Given contract opportunity Caid stocks likely undervalued, says Cantor Fitzgerald
-
TD Cowen on CIGNA (CI): 'Is a CI Re-Rating on the Horizon?'
-
CIGNA (CI) PT Raised to $365 at Cantor Fitzgerald
-
BofA Positive on UnitedHealth Group (UNH) and CVS (CVS) Reserves Positions, Negative on Humana (HUM)
-
Bernstein on Value Based Care Sector: 'We See an Attractive Set Up'
-
Bernstein SocGen on CIGNA (CI) after new COO is named
-
Cigna Corp. (CI) announces leadership changes
-
Cigna Corp. (CI) Announces 2025 Outlook Affirmation
-
Humana (HUM) Trades Lower in Sympathy with UnitedHealth Group (UNH)
-
Bernstein SocGen Group Downgrades CIGNA (CI) to Market Perform
-
CIGNA (CI) PT Lowered to $348 at Piper Sandler Following 'Large 4Q24 EPS Miss'
-
Cigna Corp. (CI) Launches Actions To Drive Positive Change for Customers and Patients
-
CIGNA (CI) PT Lowered to $355 at RBC Capital
-
CIGNA (CI) PT Lowered to $350 at Cantor Fitzgerald
-
CIGNA (CI) PT Lowered to $380 at Stephens
-
Raymond James Reiterates Strong Buy Rating on CIGNA (CI)
-
BofA on CIGNA (CI): 'Quarter and outlook disappoint, valuation pressured'
-
Cigna Corp. (CI) Misses Q4 EPS by 115c; misses on EPS forecast
-
Cigna Corp. (CI) Declares $1.51 Quarterly Dividend; 2% Yield
-
TD Cowen Assumes CIGNA (CI) at Buy
-
Cigna Corp. (CI) call put ratio 1 call to 1.7 puts into quarter results
-
Cigna Corp. (CI)option implied volatility steady as Trump administration pauses assistance program payouts
-
FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
-
House Republicans Are Eyeing A Package To Extend Govt Funding For Three Months - Punchbowl
-
Trump on drug industry: We're going to knock out the middle man
-
Bernstein Comments on Senators' Proposal to Break Up PBMs; UNH, CVS, CI Stocks Down 5-6%
-
Cigna Corp. (CI) call put ratio 1 call to 1.3 puts with focus on January calls and puts as share price down 5.2%
-
Bipartisan Legislation To Be Introduced to Force Health Insurers to Give Up Pharmacy Businesses -- WSJ
-
Cigna Corp. (CI) call put ratio 1.6 calls to 1 put with focus on January 340 calls
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Trump picks RFK Jr for HHS — Here are potential policy implications
-
Cigna Corp. (CI) is not pursuing a combination with Humana (HUM)
-
CIGNA (CI) PT Raised to $394 at Piper Sandler
-
CIGNA (CI) PT Lowered to $406 at Jefferies
